1165 related articles for article (PubMed ID: 15077129)
21. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
[TBL] [Abstract][Full Text] [Related]
22. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
[TBL] [Abstract][Full Text] [Related]
24. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
25. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
[TBL] [Abstract][Full Text] [Related]
27. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
29. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular immune response after measles vaccination in Taiwan.
Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
[TBL] [Abstract][Full Text] [Related]
31. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
32. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
[TBL] [Abstract][Full Text] [Related]
33. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
Alfredsson R; Svensson E; Trollfors B; Borres MP
Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
35. [Measles, mumps, rubella: important health risks].
Rev Infirm; 2000 Oct; (64):13-5. PubMed ID: 11288443
[No Abstract] [Full Text] [Related]
36. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
37. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
38. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
[TBL] [Abstract][Full Text] [Related]
39. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
Leuridan E; Maertens K; Wautier M; Hutse V; Theeten H
Eur J Pediatr; 2015 Jul; 174(7):925-32. PubMed ID: 25579232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
